GTX Inc. (GTXI) Stock Research, Analysis & News

Quick Analysis on GTX Inc. (GTXI) Stock as of October 21, 2017

Previous Closing Price $7.82 is below its 50 day moving average $8.03
Previous Closing Price $7.82 is above 200 day moving average of $5.70
The Stock pays no dividend
The closing price $7.82 is less than -10.49% away from its one year target price of $7.00
Current Short Ratio 8.54 is great than 1
Earning per Share $-1.71 is negative. GTX Inc. is lossing money.
EBITDA $-26.47M is negative
Average trading volume is relatively low at 32,802
It is a very small cap stock with market cap of $127.18M
(See more information about GTX Inc. (GTXI) Stock below)

GTX Inc. (GTXI) Stock Profile Summary

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions. The company markets FARESTON (toremifene citrate) 60 mg tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors in the United States. It is developing Toremifene citrate 80 mg, which completed pivotal Phase III clinical trial to reduce fractures and treat other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer; and Toremifene 20 mg that is in pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia. The company is also developing selective androgen receptor modulators comprising Ostarine, which completed Phase II clinical trials for the treatment of cancer cachexia and chronic sarcopenia; and GTx-758, an oral luteinizing hormone that completed two Phase I clinical trials for the treatment of advanced prostate cancer. It has a partnership agreement with Ipsen S.A. for the development and commercialization of toremifene 80 mg for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy and toremifene 20 mg for the prevention of prostate cancer in patients with high grade prostatic intraepithelial neoplasia lesions. GTx, Inc. was founded in 1997 and is headquartered Memphis, Tennessee.

GTX Inc. (GTXI) Stock Key Statistics Research and Analysis as of October 21, 2017

Stock ExchangeNCM
Market Capitalization$127.18M
Trade Volume (Average Trading Volume)3,806 (32,802)
Current Year EPS Estimate$-1.16
Next Year EPS Estimate$-1.16
Previous Closing Price$7.82
50 Day Price Moving Average$8.03
200 Day Price Moving Average$5.70
1 yr Target Price$7.00
PEG Ratio0.00
Short Ratio8.54

GTX Inc. (GTXI) Stock Competitor Research and Analysis

Eli Lilly & Co. (LLY)Merck & Co. Inc. (MRK)
Novartis AG (NVS)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)Mylan, Inc. (MYL)
Pfizer Inc. (PFE)Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)Sanofi-Aventis (SNY)
AstraZeneca PLC (AZN)Abbott Laboratories (ABT)

Latest Market News on GTX Inc. (GTXI)

Click here to find the latest news on GTX Inc. (GTXI)

Looking for Market Opportunties?

Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Eli Lilly & Co. (LLY)
Merck & Co. Inc. (MRK)
Novartis AG (NVS)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)